News

FDG PET Scan More Accurately Assesses Severity of Cognitive Decline in Alzheimer’s, Study Finds

Compared to regular amyloid imaging, fluorodeoxyglucose positron emission tomography (FDG PET), an imaging technique that quantifies brain function by measuring glucose levels, can better assess the progression and severity of cognitive decline in people with Alzheimer’s, and also cognitive impairment, researchers have found. Their study, “18F-FDG Is…

Protein Treatment, GRF6019, Seen to Help Maintain Cognition in Alzheimer’s Patients in Phase 2 Trial

Alkahest’s experimental blood-derived protein GRF6019 helps maintain cognition and function in mild to moderate Alzheimer’s disease patients, results of a six-month Phase 2 clinical trial show. “These top-line results indicate a potential benefit of this plasma protein fraction in slowing the progression of cognitive decline in patients with…